Amgen Inc. vs Hitachi, Ltd.: Strategic Comparison

This in-depth comparison examines Amgen Inc. and Hitachi, Ltd. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating Hitachi, Ltd., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and Hitachi, Ltd. is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against ~$70.9B for Hitachi, Ltd., while their respective market capitalizations stand at $228.2B and $157.8B. Amgen Inc. is headquartered in United States and Hitachi, Ltd. in Japan, and those different home markets shape how each company competes.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

Hitachi, Ltd.: Hitachi is a Japanese industrial technology group founded in 1910 and headquartered in Chiyoda, Tokyo. It is listed on the Tokyo Stock Exchange (6501), had 287,901 employees at March 31, 2026, and is led by President and CEO Toshiaki Tokunaga, with Keiji Kojima as Executive Chairman. Many people still link the name to TVs, hard drives, or home appliances, but those businesses have been sold or are being sold. Today's Hitachi builds power grid equipment through Hitachi Energy, trains and signalling through Hitachi Rail, IT systems and digital engineering through its Digital Systems & Services sector and GlobalLogic, and industrial and building equipment through Connective Industries.

Amgen Inc. and Hitachi, Ltd. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and Hitachi, Ltd..

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

Hitachi, Ltd. business model: Hitachi is a B2B infrastructure and IT company. It sells long-lived physical assets (transformers, HVDC converter stations, trains, signalling, elevators, semiconductor metrology tools) and then earns recurring service, maintenance, and software revenue on that installed base. Lumada is the umbrella for the data, AI, and digital services layered on top, and Hitachi reports Lumada as a growing share of total revenue. The four reporting sectors are Digital Systems & Services, Energy, Mobility, and Connective Industries. Customers are utilities, rail operators, governments, banks, and manufacturers, and many contracts run for years, which gives Hitachi a large order backlog and revenue visibility.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of Hitachi, Ltd..

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

Hitachi, Ltd. competitive advantage: Hitachi's edge is owning both the operational technology and the IT. Hitachi Energy (built on ABB's former Power Grids business) is one of a handful of suppliers able to deliver HVDC links and large power transformers at scale, Hitachi Rail became a top-tier signalling supplier after buying Thales GTS in 2024, and GlobalLogic plus Hitachi's Japanese IT business supply the software. Few rivals combine all three, and the installed base of grids, trains, and IT systems feeds long-term service revenue.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and Hitachi, Ltd. each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

Hitachi, Ltd. growth strategy: Hitachi grows by attaching software and services to its installed base and by reshaping its portfolio. It is expanding Hitachi Energy factory capacity for transformers and HVDC, integrating Thales GTS into Hitachi Rail, and scaling Lumada through GlobalLogic and AI partnerships. On the portfolio side, it agreed in April 2026 to sell 80.1% of its home appliance business to Nojima for about $737 million (¥110 billion), continuing a long exit from consumer and commodity businesses.

A closer look at the financial trajectory of Amgen Inc. and Hitachi, Ltd. rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

Hitachi, Ltd.: Hitachi posted a ~$5.27 billion (¥787.3 billion) net loss for fiscal 2008, then the largest ever by a Japanese manufacturer. Under Takashi Kawamura and Hiroaki Nakanishi it cut loss-making consumer businesses, and later leaders sold listed subsidiaries such as Hitachi Chemical (2020), Hitachi Metals (2023), and a controlling stake in Hitachi Construction Machinery (2022). Revenue dipped from ~$72.9 billion (¥10.88 trillion) in FY2022 to ~$65.2 billion (¥9.73 trillion) in FY2023 as those units left, then climbed back to ~$71 billion (¥10.59 trillion) in FY2025 on organic growth. FY2025 adjusted EBITA was a record ~$8.78 billion (¥1.31 trillion) (12.4% margin) and net income was ~$5.38 billion (¥802.3 billion), up about 30%. In Q1 FY2026 (April-June 2026) revenue rose 20% to ~$18.2 billion (¥2,709.6 billion), helped by currency, and management raised full-year guidance.